Literature DB >> 17075818

HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies.

Terrance P O'Hanlon1, Lisa G Rider, Gulnara Mamyrova, Ira N Targoff, Frank C Arnett, John D Reveille, Mary Carrington, Xiaojiang Gao, Chester V Oddis, Penelope A Morel, James D Malley, Karen Malley, Ejaz A Shamim, Stephen J Chanock, Charles B Foster, Thomas Bunch, Ann M Reed, Lori A Love, Frederick W Miller.   

Abstract

OBJECTIVE: To investigate possible associations of HLA polymorphisms with idiopathic inflammatory myopathy (IIM) in African Americans, and to compare this with HLA associations in European American IIM patients with IIM.
METHODS: Molecular genetic analyses of HLA-A, B, Cw, DRB1, and DQA1 polymorphisms were performed in a large population of African American patients with IIM (n = 262) in whom the major clinical and autoantibody subgroups were represented. These data were compared with similar information previously obtained from European American patients with IIM (n = 571).
RESULTS: In contrast to European American patients with IIM, African American patients with IIM, in particular those with polymyositis, had no strong disease associations with HLA alleles of the 8.1 ancestral haplotype; however, African Americans with dermatomyositis or with anti-Jo-1 autoantibodies shared the risk factor HLA-DRB1*0301 with European Americans. We detected novel HLA risk factors in African American patients with myositis overlap (DRB1*08) and in African American patients producing anti-signal recognition particle (DQA1*0102) and anti-Mi-2 autoantibodies (DRB1*0302). DRB1*0302 and the European American-, anti-Mi-2-associated risk factor DRB1*0701 were found to share a 4-amino-acid sequence motif, which was predicted by comparative homology analyses to have identical 3-dimensional orientations within the peptide-binding groove.
CONCLUSION: These data demonstrate that North American IIM patients from different ethnic groups have both shared and distinct immunogenetic susceptibility factors, depending on the clinical phenotype. These findings, obtained from the largest cohort of North American minority patients with IIM studied to date, add additional support to the hypothesis that the myositis syndromes comprise multiple, distinct disease entities, perhaps arising from divergent pathogenic mechanisms and/or different gene-environment interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075818     DOI: 10.1002/art.22205

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

Review 2.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

3.  Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Daniel Gaudet; Diane Brisson; Lisa Christopher-Stine; Thomas E Lloyd; Mary S Leffell; Andrea A Zachary
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

Review 4.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

5.  Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.

Authors:  Sarah Samandary; Hédia Kridane-Miledi; Jacqueline S Sandoval; Zareen Choudhury; Francina Langa-Vives; Doran Spencer; Aziz A Chentoufi; François A Lemonnier; Lbachir BenMohamed
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

6.  Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Authors:  Ruxue Yin; Gangjian Wang; Lei Zhang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

7.  The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.

Authors:  Ya-Mei Zhang; Han-Bo Yang; Jing-Li Shi; He Chen; Xiao-Ming Shu; Xin Lu; Guo-Chun Wang; Qing-Lin Peng
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

8.  Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Adam Schiffenbauer; Ira N Targoff; Karen Malley; Janardan P Pandey; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2008-10

9.  Genetic risk and protective factors for the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Frederick W Miller
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

10.  Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

Authors:  K P Ng; F Ramos; S M Sultan; D A Isenberg
Journal:  Clin Rheumatol       Date:  2009-04-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.